AcelRx Pharmaceuticals Inc (ACRX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:AcelRx Pharmaceuticals Inc (ACRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9866
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
AcelRx Pharmaceuticals Inc (AcelRx), is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain. The company’s lead product candidate, Dsuvia (known as Dzuveo outside the US), is a single sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. Its pipeline also includes Zalviso, a drug and device combination product for management of moderate to severe acute pain in adults. AcelRx developed a proprietary, non-invasive, sublingual formulation technology to deliver its highly lipophilic drugs. The company commercializes its EC approved Zalviso under license agreement with Grunenthal in various European Union countries and Australia. AcelRx is headquartered in Redwood City, California, the US.

AcelRx Pharmaceuticals Inc (ACRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
AcelRx Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
Leerink Revelation and Industry Ventures Acquire Stake in AcelRx Pharma 11
Partnerships 12
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 12
Equity Offering 14
AcelRx Pharma Raises USD23 Million in Public Offering of Shares 14
Acelrx Pharma Plans to Raise USD40 Million in Public Offering of Shares 16
AcelRx Pharma Completes Public Offering Of Shares For US$51 Million 17
AcelRx Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For US$6 Million 19
AcelRx Pharma Completes Private Placement Of Units For US$10 Million 21
Asset Transactions 22
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 22
AcelRx Pharmaceuticals Inc – Key Competitors 24
AcelRx Pharmaceuticals Inc – Key Employees 25
AcelRx Pharmaceuticals Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Nov 02, 2018: Acelrx Pharmaceuticals reports third quarter 2018 financial results and provides corporate update 27
Aug 02, 2018: AcelRx Pharmaceuticals reports second quarter 2018 financial results 28
May 09, 2018: AcelRx Pharmaceuticals Reports First Quarter 2018 Financial Results 29
Mar 08, 2018: AcelRx Pharmaceuticals Reports Fourth Quarter 2017 Financial Results 30
Nov 09, 2017: AcelRx Pharmaceuticals Reports Third Quarter 2017 Financial Results 31
Aug 01, 2017: AcelRx Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 32
May 08, 2017: AcelRx Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 34
Mar 02, 2017: AcelRx Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results 36
Corporate Communications 38
Oct 12, 2018: AcelRx Pharmaceuticals Stock Trading Halted 38
Jul 19, 2017: AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer 39
Feb 16, 2017: AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AcelRx Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
AcelRx Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Leerink Revelation and Industry Ventures Acquire Stake in AcelRx Pharma 11
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 12
AcelRx Pharma Raises USD23 Million in Public Offering of Shares 14
Acelrx Pharma Plans to Raise USD40 Million in Public Offering of Shares 16
AcelRx Pharma Completes Public Offering Of Shares For US$51 Million 17
AcelRx Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$6 Million 19
AcelRx Pharma Completes Private Placement Of Units For US$10 Million 21
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 22
AcelRx Pharmaceuticals Inc, Key Competitors 24
AcelRx Pharmaceuticals Inc, Key Employees 25
AcelRx Pharmaceuticals Inc, Subsidiaries 26

List of Figures
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
AcelRx Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[AcelRx Pharmaceuticals Inc (ACRX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PetroChina Co Ltd (857):石油・ガス:M&Aディール及び事業提携情報
    Summary PetroChina Co Ltd (PetroChina) operates a subsidiary of China National Petroleum Corporation. It is an oil and gas company that explores for and develops and produces crude oil and natural gas; refines crude oil and petroleum products; and produces and sells basic and derivative chemical pro …
  • Mid-America Apartment Communities Inc (MAA):企業の財務・戦略的SWOT分析
    Summary Mid-America Apartment Communities, Inc. (MAA) is a real estate investment company that operates apartment homes. The company is engaged in property development, property management, redevelopment, acquisition, sales, marketing and financing. MAA provides web-based and technology driven suppo …
  • Angel Yeast Co Ltd:企業の戦略・SWOT・財務情報
    Angel Yeast Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Angel Yeast Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • PharmaCyte Biotech Inc (PMCB):企業の財務・戦略的SWOT分析
    Summary PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc, is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company offers technology is used for the treatment of advanced and inoperable pancreatic cancer and diabetes. It deve …
  • Millennium & Copthorne Hotels Plc:戦略・SWOT・企業財務分析
    Millennium & Copthorne Hotels Plc - Strategy, SWOT and Corporate Finance Report Summary Millennium & Copthorne Hotels Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Empresa Nacional del Petroleo:石油・ガス:M&Aディール及び事業提携情報
    Summary Empresa Nacional del Petroleo (ENAP) is a state-owned integrated oil and gas company. It carries out exploration, development and production of hydrocarbons. The company has major upstream operations in Magallanes region of Chile. ENAP also carries out refining, transportation, storage, and …
  • Nanobiotix SA (NANO):企業の財務・戦略的SWOT分析
    Summary Nanobiotix SA (Nanobiotix) designs and manufactures nanomedicines for the treatment of cancer. The company is evaluating its lead product candidate NBTXR3 against soft tissue sarcoma, pancreatic, liver, rectal, prostate, head and neck cancers; Non-small cell lung cancer (NSCLC); recurrent he …
  • Vertex Pharmaceuticals Inc (VRTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Vertex Pharmaceuticals Inc (Vertex) is a biotechnology company that carries out the discovery, development and commercialization of transformative drugs for the treatment of serious and life-threatening diseases. The company product portfolio includes Orkambi (ivacaftor/lumacaftor) and Kalyd …
  • Unchained Labs-製薬・医療分野:企業M&A・提携分析
    Summary Unchained Labs is a life science tools company which offers protein stability assessment products for biologics. Its product portfolio includes UNcle (biologics stability platform), HUNK (aggregation predictor), pUNk (protein sizing system), GRUNT (automated formulation preparation system), …
  • Blue Label Telecoms Ltd (BLU):企業の財務・戦略的SWOT分析
    Blue Label Telecoms Ltd (BLU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Sygnis AG (LIO1):医療機器:M&Aディール及び事業提携情報
    Summary Sygnis AG (Sygnis), formerly Sygnis Pharma AG is a developer of novel products and tools in the field of molecular biology. The company undertakes development and marketing of new molecular biological technologies for DNA amplification and sequencing. Its offers products such as single cell …
  • Cabot Corp (CBT):企業の財務・戦略的SWOT分析
    Cabot Corp (CBT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Mereo Biopharma Group Plc (MPH):企業の財務・戦略的SWOT分析
    Summary Mereo Biopharma Group Plc (Mereo), formerly Mereo Biopharma Group Ltd is a specialty bio-pharmaceutical company which develops novel medicines for the treatment of rare and specialty diseases. The company’s pipeline products include BPS-804, which is used for the treatment of brittle bone sy …
  • Dril-Quip Inc (DRQ):企業の財務・戦略的SWOT分析
    Dril-Quip Inc (DRQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Valero Energy Corporation (VLO)-石油・ガス分野:企業M&A・提携分析
    Summary Valero Energy Corporation (Valero) is a manufacturer and marketer of transportation fuels, petrochemical products and power. The company’s assets include petroleum refineries, ethanol plants, a wind farm and renewable diesel production from a joint venture. Its refineries produce gasoline, d …
  • Arete Industries Inc (ARET):企業の財務・戦略的SWOT分析
    Summary Arete Industries Inc (Arete Industries) is an oil and gas company that operates pipeline stations. The company operates a natural gas gathering system located in Campbell County, Wyoming. Arete Industries gas gathering systems comprise coated steel pipeline transporting coal bed methane. The …
  • Deep Well Oil & Gas Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Deep Well Oil & Gas Inc (Deep Well Oil & Gas) is an oil and gas exploration and development company that acquires, explores and develops oil sands. The company operates HCSS Thermal Recovery Project and SAGD Thermal Recovery Project. Its SAGD Thermal Recovery Project operates Sawn Lake oil s …
  • China Power Clean Energy Development Co Ltd (735):企業の財務・戦略的SWOT分析
    China Power Clean Energy Development Co Ltd (735) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • PositiveID Corp (PSID):企業の財務・戦略的SWOT分析
    Summary PositiveID Corp (PositiveID), formerly VeriChip Corp is a life sciences tools and diagnostics company that develops biological detection and molecular diagnostic systems. The company develops microfluidic systems for automated preparation and performance of biological assays. Its products in …
  • Jiangsu Hengrui Medicine Co Ltd (600276):製薬・医療:M&Aディール及び事業提携情報
    Summary Jiangsu Hengrui Medicine Co Ltd (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture and distribution of novel pharmaceutical products. Its product portfolio includes antineoplastic products, anti-tumor drugs, surgical drugs and contrast age …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆